Use of levodopa decarbozylase inhibitor

PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR

No definition available.

Endpoint definition

FinnGen phenotype data

321302 individuals

diagram downward connector

Apply sex-specific rule None

321302

diagram downward connector

Check conditions None

321302

diagram downward connector
diagram bullet

Filter registries

Medicine purchases: ATC N04BA02

3440

diagram downward connector

Check pre-conditions, main-only, mode, ICD version None

2673

diagram downward connector
diagram bullet

Check minimum number of events

Min. number of events 3

2673

diagram downward connector

Include endpoints None

2673

diagram downward connector
PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR

Extra metadata

First used in FinnGen datafreeze DF2

Summary Statistics

Key figures

All Female Male
Number of individuals 2599 1083 1516
Unadjusted prevalence (%) 0.84 0.62 1.12
Mean age at first event (years) 68.85 67.84 69.57

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.05 3.92 [3.21, 4.77] 9.8e-42 766
15 years 0.01 2.17 [1.79, 2.63] 2.7e-15 397
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR – Use of levodopa decarbozylase inhibitor
GWS hits:

Survival analyses between endpoints

Plot

before Use of levodopa decarbozylase inhibitor
after Use of levodopa decarbozylase inhibitor

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Use of levodopa decarbozylase inhibitor